ALLMedicine™ Alveolar Soft Part Sarcoma Center

Aug 5th, 2022 - Background: Alveolar soft part sarcoma (ASPS) is a rare, highly vascular tumor accounting for less than 1% of soft tissue sarcomas. There is no effective systemic treatment for patients with metastatic ASPS. Little is known with regards to relevan...

Jul 19th, 2022 - Identical TFE3-related gene fusions may be found in renal cell carcinoma and mesenchymal neoplasms such as alveolar soft part sarcoma and TFE3-rearranged perivascular epithelioid cell tumor (PEComa). Among mesenchymal neoplasms, the ASPSCR1-TFE3 g...

Jul 9th, 2022 - Alveolar soft part sarcoma (ASPS) is a rare soft tissue sarcoma harboring an ASPL-TFE3 fusion gene. Herein, we report a case of ASPS associated with brain metastasis. Immunohistochemistry (IHC) for TFE3 antigen expression and fluorescence in situ ...

Jul 6th, 2022 - PRIMARY OBJECTIVE: I. Determine the overall response rate (by Response Evaluation Criteria in Solid Tumors [RECIST] version [v]1.1) for selinexor in combination with atezolizumab in immune checkpoint inhibitor (ICI)-naive patients with alveolar so...

Jun 30th, 2022 - PRIMARY OBJECTIVES: I. Determine the objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 of atezolizumab in patients with advanced alveolar soft part sarcoma (ASPS) in adult subjects >= 18 year...

Aug 5th, 2022 - Background: Alveolar soft part sarcoma (ASPS) is a rare, highly vascular tumor accounting for less than 1% of soft tissue sarcomas. There is no effective systemic treatment for patients with metastatic ASPS. Little is known with regards to relevan...

Jul 6th, 2022 - PRIMARY OBJECTIVE: I. Determine the overall response rate (by Response Evaluation Criteria in Solid Tumors [RECIST] version [v]1.1) for selinexor in combination with atezolizumab in immune checkpoint inhibitor (ICI)-naive patients with alveolar so...

Jun 30th, 2022 - PRIMARY OBJECTIVES: I. Determine the objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 of atezolizumab in patients with advanced alveolar soft part sarcoma (ASPS) in adult subjects >= 18 year...

Mar 22nd, 2022 - Background: Alveolar soft part sarcoma (ASPS) is a rare, highly vascular tumor accounting for less than 1% of soft tissue sarcomas. There is no effective systemic treatment for patients with metastatic ASPS. Little is known with regards to relevan...

Nov 26th, 2021 - Arm 2, the Axitinib Plus Pembrolizumab Expansion Cohort, did not open.

Oct 6th, 2021 - Jonathan C. Trent, MD, PhD Anlotinib, a novel tyrosine kinase inhibitor capable of mounting a multipronged attack against oncogenic processes, is being tested in rare soft tissue sarcoma subtypes where patients have limited therapeutic options. ...

Oct 6th, 2021 - Neeta Somaiah, MD Therapeutic advances in soft tissue sarcoma have occurred across several subtypes, and more research efforts continue to be conducted with novel agents targeting NY-ESO-1 and MAGE-A4, for example, explained Neeta Somaiah, MD. F...

Oct 6th, 2021 - Jonathan C. Trent, MD, PhD Soft tissue sarcoma treatments have significantly advanced within the past year with new available agents, others in the pipeline, and the continued search for biomarkers to make treatment more personalized for patients...

Apr 2nd, 2021 - Transcript:William D. Tap, MD: One of the things I want to get back to is this comment that sarcoma is a chemotherapy-insensitive disease. I’m sure we can talk about, and we will, some diseases that are chemotherapy-insensitive. But what’s your th...

Apr 2nd, 2021 - Transcript: Neeta Somaiah, MD: I think that’s a good transition point to talk about what you think are the biggest unmet needs in patients with sarcoma. Again, I know this is a broad statement, and I’m sure there are unmet needs for patients wi...